Microbial diversity in infections of patients with medication-related osteonecrosis of the jaw.
Actinomyces
Aged
Aged, 80 and over
Bacterial Infections
/ complications
Bisphosphonate-Associated Osteonecrosis of the Jaw
/ microbiology
Bone Density Conservation Agents
/ adverse effects
Breast Neoplasms
/ complications
Diphosphonates
Female
Humans
Male
Middle Aged
Prevotella
Prostatic Neoplasms
/ complications
Streptococcus
Veillonella
Zoledronic Acid
/ adverse effects
Antibiotic treatment
Bone and soft tissue infections
MRONJ
Osteonecrosis of the jaws
Pathogenic biofilms
Relevant pathogens
Journal
Clinical oral investigations
ISSN: 1436-3771
Titre abrégé: Clin Oral Investig
Pays: Germany
ID NLM: 9707115
Informations de publication
Date de publication:
May 2019
May 2019
Historique:
received:
24
03
2018
accepted:
20
09
2018
pubmed:
3
10
2018
medline:
28
12
2019
entrez:
3
10
2018
Statut:
ppublish
Résumé
A central role of infections in the treatment of MRONJ patients is widely accepted. An investigation of the MRONJ lesions' biofilms as potential pathogens seems logical. We investigated the clinical data of our MRONJ patients who received surgery in advanced stage of the disease. Special attention was granted to the local colonizers harvested from osseous MRONJ specimens and submucosal putrid infections. Eleven out of 71 patients presented a spontaneous onset of the disease and for 60 out of 71 patients a trigger was detected. Breast cancer (29.6%) and prostate cancer (22.5%) were the most frequent underlying disease for prescription of an antiresorptive therapy, mostly zoledronate. Submucosal soft tissue biofilms significantly differed from biofilms harvested from the MRONJ lesions bottom, yet the most frequent bacteria were equally present in both groups: Streptococcus species (spp.), Prevotella spp., Actinomyces spp., Veillonella spp., and Parvimonas micra. The cephalosporins, cefuroxime and cefotaxime, and ß-lactam antibiotics with ß-lactamase inhibitor revealed the greatest susceptibility for the detected bacteria. The bacteria from the submucosal areas and the bottom of the infected bone presented comparable susceptibility to the common antibiotics regimes. Streptococcus spp., Prevotella spp., and Veillonella spp. present a high abundance in MRONJ lesions beside Actinomyces spp. The MRONJ lesions bottom is in many cases not infected by Actinomyces spp. The removal of the necrotic bone reduces the variety of bacteria found in MRONJ lesions, in particular at the bottom of the lesion.
Identifiants
pubmed: 30276516
doi: 10.1007/s00784-018-2655-z
pii: 10.1007/s00784-018-2655-z
doi:
Substances chimiques
Bone Density Conservation Agents
0
Diphosphonates
0
Zoledronic Acid
6XC1PAD3KF
Types de publication
Journal Article
Langues
eng
Pagination
2143-2151Références
Clin Microbiol Rev. 2001 Apr;14(2):244-69
pubmed: 11292638
Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004 Oct;98(4):398-408
pubmed: 15472653
J Antimicrob Chemother. 2005 Aug;56(2):407-9
pubmed: 15972310
Anaerobe. 2008 Feb;14(1):1-7
pubmed: 18222714
South Med J. 2008 Oct;101(10):1019-23
pubmed: 18791528
J Oral Maxillofac Surg. 2009 May;67(5 Suppl):2-12
pubmed: 19371809
Clin Oral Investig. 2010 Jun;14(3):271-84
pubmed: 19536569
Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2009 Nov;108(5):738-46
pubmed: 19748292
J Oral Maxillofac Surg. 2011 Nov;69(11):e364-71
pubmed: 21782307
Oral Dis. 2012 Jan;18(1):85-95
pubmed: 21883710
Br J Oral Maxillofac Surg. 2012 Jul;50(5):425-9
pubmed: 21907470
Ann Oncol. 2012 May;23(5):1341-7
pubmed: 21986094
BMJ. 2011 Oct 11;343:d6099
pubmed: 21990282
Oral Oncol. 2012 Apr;48(4):349-54
pubmed: 22130456
Oral Dis. 2012 Sep;18(6):602-12
pubmed: 22443347
Clin Cases Miner Bone Metab. 2007 Jan;4(1):53-7
pubmed: 22460754
J Oral Maxillofac Surg. 2012 Nov;70(11):2501-7
pubmed: 22883322
Med Oral Patol Oral Cir Bucal. 2012 Nov 01;17(6):e948-55
pubmed: 22926469
Oral Surg Oral Med Oral Pathol Oral Radiol. 2012 Dec;114(6):764-70
pubmed: 23159114
J Oral Pathol Med. 2013 Sep;42(8):587-93
pubmed: 23369166
J Oral Pathol Med. 2014 Jul;43(6):448-53
pubmed: 24456519
Future Oncol. 2014 Feb;10(2):257-75
pubmed: 24490612
Arch Oral Biol. 2014 Aug;59(8):790-9
pubmed: 24859766
Eur J Clin Microbiol Infect Dis. 2014 Nov;33(11):1873-80
pubmed: 24880820
Int J Mol Med. 2014 Aug;34(2):559-63
pubmed: 24920042
Int J Dent. 2014;2014:452737
pubmed: 25089126
Int J Oral Sci. 2014 Dec;6(4):219-26
pubmed: 25105817
J Oral Maxillofac Surg. 2014 Oct;72(10):1938-56
pubmed: 25234529
J Dent Res. 2015 Apr;94(4):534-9
pubmed: 25710950
J Oral Maxillofac Surg. 2015 Jul;73(7):1288-95
pubmed: 25871903
J Clin Periodontol. 2015 Oct;42(10):922-32
pubmed: 26362756
Oral Maxillofac Surg. 2016 Mar;20(1):9-17
pubmed: 26659615
Ther Clin Risk Manag. 2015 Dec 04;11:1779-88
pubmed: 26675713
J Bone Metab. 2015 Nov;22(4):151-65
pubmed: 26713306
Sci Rep. 2016 Aug 17;6:31604
pubmed: 27530150
J Craniomaxillofac Surg. 2016 Oct;44(10):1694-1699
pubmed: 27591091
Stem Cells Int. 2016;2016:8768162
pubmed: 27721837
J Clin Densitom. 2017 Jan - Mar;20(1):8-24
pubmed: 27956123
J Clin Exp Dent. 2017 Jan 1;9(1):e141-e149
pubmed: 28149479
Oral Surg Oral Med Oral Pathol Oral Radiol. 2017 Apr;123(4):436-444
pubmed: 28159588
J Craniomaxillofac Surg. 2017 Mar;45(3):357-363
pubmed: 28162845
J Clin Exp Dent. 2017 Feb 1;9(2):e302-e307
pubmed: 28210453
J Bone Miner Res. 2017 Oct;32(10):2022-2029
pubmed: 28585700
MBio. 2017 Jun 20;8(3):
pubmed: 28634238
J Craniomaxillofac Surg. 2017 Aug;45(8):1183-1189
pubmed: 28684074
J Korean Assoc Oral Maxillofac Surg. 2017 Aug;43(4):282-285
pubmed: 28875145
Cochrane Database Syst Rev. 2017 Oct 06;10:CD012432
pubmed: 28983908
Eur J Cancer Care (Engl). 2017 Nov;26(6):null
pubmed: 29063702
J Craniomaxillofac Surg. 2017 Dec;45(12):2068-2074
pubmed: 29102331
Dent J (Basel). 2016 Oct 25;4(4):null
pubmed: 29563478
Laryngoscope. 1984 Sep;94(9):1198-217
pubmed: 6381942
Clin Infect Dis. 1994 May;18 Suppl 4:S253-9
pubmed: 8086573